The Experts below are selected from a list of 219 Experts worldwide ranked by ideXlab platform
A. Atilla Hincal - One of the best experts on this subject based on the ideXlab platform.
-
Formulation, bioavailability, and pharmacokinetics of sustained-release Potassium Chloride tablets.
Pharmaceutical research, 1991Co-Authors: S. Senel, Yilmaz Capan, Turgay Dalkara, N Inanç, A. Atilla HincalAbstract:The release of Potassium Chloride incorporated into hydrogenated vegetable oil and hydroxypropyl methylcellulose matrix tablets was studied in vitro. The formulations containing 20% hydrogenated vegetable oil and hydroxypropyl methylcellulose showed a sustained-release profile comparable to that of a standard commercially available sustained-release preparation, containing 8 mEq Potassium Chloride embedded in a wax material. The formulated and standard sustained-release Potassium Chloride tablets were compared to a conventional enteric-coated Potassium Chloride tablet in 10 healthy subjects. Mean recoveries in 24-hr urine Potassium levels from four dosage forms (after subtracting normal urine Potassium excretion levels) were 76 ± 32% from hydroxypropyl methylcellulose, 95 ± 22% from hydrogenated vegetable oil-incorporated matrix tablets, 91 ± 29% from commercially available sustained-release tablets, and 97 ± 13% from enteric-coated tablets. There was no significant difference (P > 0.05) in the time to reach maximum excretion rates among the three sustained-release tablets. No significant adverse effect was experienced with any of the preparations.
A. Arancibia - One of the best experts on this subject based on the ideXlab platform.
-
Development of a Formulation of Sustained Release Potassium Chloride
Drug Development and Industrial Pharmacy, 1991Co-Authors: R. Pezoa, O. Jopia, A. M. Monardes, A. ArancibiaAbstract:AbstractThe purpose of this work has been the designing and “in vitro” evaluation of a Potassium Chloride tablet using a wax matrix.Camauba wax, stearyl alcohol and stearic acid ware employed to prepare granulates at different drug/wax ratios. Fran dissolution kinetic studies and technological performances a 75/25 – KCl/camauba wax granulates was selected. The rheolqgical properties of granulates were characterized and tablets were manufactured employing ccrrmun tablets excipients. Also a coating procedure was developed. The coated tablet formulation selected release the Potassium Chloride according to the USP requirements.The dissolution kinetics of the Potassium Chloride from both coated and uncoated tablets fit the Higuchi diffusion model, giving a straight line when the amount dissolved is plotted against the square root of time.
S. Senel - One of the best experts on this subject based on the ideXlab platform.
-
Formulation, bioavailability, and pharmacokinetics of sustained-release Potassium Chloride tablets.
Pharmaceutical research, 1991Co-Authors: S. Senel, Yilmaz Capan, Turgay Dalkara, N Inanç, A. Atilla HincalAbstract:The release of Potassium Chloride incorporated into hydrogenated vegetable oil and hydroxypropyl methylcellulose matrix tablets was studied in vitro. The formulations containing 20% hydrogenated vegetable oil and hydroxypropyl methylcellulose showed a sustained-release profile comparable to that of a standard commercially available sustained-release preparation, containing 8 mEq Potassium Chloride embedded in a wax material. The formulated and standard sustained-release Potassium Chloride tablets were compared to a conventional enteric-coated Potassium Chloride tablet in 10 healthy subjects. Mean recoveries in 24-hr urine Potassium levels from four dosage forms (after subtracting normal urine Potassium excretion levels) were 76 ± 32% from hydroxypropyl methylcellulose, 95 ± 22% from hydrogenated vegetable oil-incorporated matrix tablets, 91 ± 29% from commercially available sustained-release tablets, and 97 ± 13% from enteric-coated tablets. There was no significant difference (P > 0.05) in the time to reach maximum excretion rates among the three sustained-release tablets. No significant adverse effect was experienced with any of the preparations.
Lina Matta - One of the best experts on this subject based on the ideXlab platform.
-
Potassium Chloride Sustained Release Dosing Pathway in an Academic Medical Center.
Critical pathways in cardiology, 2017Co-Authors: Bryan M. Cook, Danielle Carter, Heather Dell’orfano, Lina MattaAbstract:Potassium supplementation can be administered intravenously or orally with either immediate release or sustained release formulations. Sustained release Potassium Chloride allows for delayed absorption and peak effects. In the inpatient setting, it is important to monitor and prevent both hypokalemia and hyperkalemia. Our tertiary-care academic hospital created a clinical pathway for sustained release Potassium Chloride supplementation in the inpatient population. Our clinical pathway for sustained release Potassium Chloride creates dosing restrictions designed to prevent hyperkalemia, while allowing exceptions for patients with high requirements.
Turgay Dalkara - One of the best experts on this subject based on the ideXlab platform.
-
Formulation, bioavailability, and pharmacokinetics of sustained-release Potassium Chloride tablets.
Pharmaceutical research, 1991Co-Authors: S. Senel, Yilmaz Capan, Turgay Dalkara, N Inanç, A. Atilla HincalAbstract:The release of Potassium Chloride incorporated into hydrogenated vegetable oil and hydroxypropyl methylcellulose matrix tablets was studied in vitro. The formulations containing 20% hydrogenated vegetable oil and hydroxypropyl methylcellulose showed a sustained-release profile comparable to that of a standard commercially available sustained-release preparation, containing 8 mEq Potassium Chloride embedded in a wax material. The formulated and standard sustained-release Potassium Chloride tablets were compared to a conventional enteric-coated Potassium Chloride tablet in 10 healthy subjects. Mean recoveries in 24-hr urine Potassium levels from four dosage forms (after subtracting normal urine Potassium excretion levels) were 76 ± 32% from hydroxypropyl methylcellulose, 95 ± 22% from hydrogenated vegetable oil-incorporated matrix tablets, 91 ± 29% from commercially available sustained-release tablets, and 97 ± 13% from enteric-coated tablets. There was no significant difference (P > 0.05) in the time to reach maximum excretion rates among the three sustained-release tablets. No significant adverse effect was experienced with any of the preparations.